| Primary prophylaxis for hospitalized medical patients with cancer |
| Thromboprophylaxis vs no thromboprophylaxis |
| LMWH vs UFH |
| Combination of methods vs pharmacological thromboprophylaxis |
| Mechanical vs pharmacological thromboprophylaxis |
| Continuation of thromboprophylaxis at home vs discontinuation at time of discharge |
| Primary prophylaxis for patients with cancer undergoing surgery |
| Pharmacological vs mechanical thromboprophylaxis |
| Combination of pharmacologic and mechanical prophylaxis vs mechanical thromboprophylaxis alone |
| Combination of pharmacologic and mechanical prophylaxis vs pharmacological thromboprophylaxis alone |
| LMWH vs UFH |
| Fondaparinux vs LMWH |
| Preoperative thromboprophylaxis vs immediate postoperative thromboprophylaxis |
| Extended (continue at home) vs limited (7-10 d; discontinue at the time of discharge) |
| Primary prophylaxis for ambulatory patients with cancer receiving systemic therapy |
| Parenteral thromboprophylaxis vs no thromboprophylaxis |
| VKA thromboprophylaxis vs no thromboprophylaxis |
| DOAC thromboprophylaxis vs no thromboprophylaxis |
| Low-dose ASA thromboprophylaxis vs fixed-dose VKA |
| Low-dose ASA vs LMWH |
| Primary prophylaxis for patients with cancer with CVC |
| Parenteral thromboprophylaxis vs no thromboprophylaxis |
| Oral thromboprophylaxis vs no thromboprophylaxis |
| Initial treatment (within first week) for patients with cancer |
| LMWH vs UFH |
| Fondaparinux vs LMWH |
| DOAC vs LMWH |
| Short-term treatment for patients with active cancer (initial 3-6 mo) |
| LMWH vs VKA |
| DOAC vs VKA |
| DOAC vs LMWH |
| Short-term treatment (3-6 mo) vs observation for patients with cancer and incidental PE |
| Short-term treatment (3-6 mo) vs observation for patients with cancer and SSPE |
| Short-term treatment (3-6 mo) vs observation for patients with cancer and visceral/splanchnic vein thrombosis |
| Keeping CVC vs removing CVC |
| Increasing dose to supratherapeutic levels vs continuing with standard therapeutic dose |
| Adding an IVC filter vs not for patients with cancer and recurrent VTEs, despite therapeutic anticoagulation treatment |
| Long-term treatment (>6 mo) for patients with active cancer and VTE |
| Long-term anticoagulation (>6 mo) vs short-term anticoagulation (3-6 mo) |
| Continuing indefinite anticoagulation vs stopping after completion of a definitive period of anticoagulation |
| DOAC vs LMWH for long-term anticoagulation |
| Primary prophylaxis for hospitalized medical patients with cancer |
| Thromboprophylaxis vs no thromboprophylaxis |
| LMWH vs UFH |
| Combination of methods vs pharmacological thromboprophylaxis |
| Mechanical vs pharmacological thromboprophylaxis |
| Continuation of thromboprophylaxis at home vs discontinuation at time of discharge |
| Primary prophylaxis for patients with cancer undergoing surgery |
| Pharmacological vs mechanical thromboprophylaxis |
| Combination of pharmacologic and mechanical prophylaxis vs mechanical thromboprophylaxis alone |
| Combination of pharmacologic and mechanical prophylaxis vs pharmacological thromboprophylaxis alone |
| LMWH vs UFH |
| Fondaparinux vs LMWH |
| Preoperative thromboprophylaxis vs immediate postoperative thromboprophylaxis |
| Extended (continue at home) vs limited (7-10 d; discontinue at the time of discharge) |
| Primary prophylaxis for ambulatory patients with cancer receiving systemic therapy |
| Parenteral thromboprophylaxis vs no thromboprophylaxis |
| VKA thromboprophylaxis vs no thromboprophylaxis |
| DOAC thromboprophylaxis vs no thromboprophylaxis |
| Low-dose ASA thromboprophylaxis vs fixed-dose VKA |
| Low-dose ASA vs LMWH |
| Primary prophylaxis for patients with cancer with CVC |
| Parenteral thromboprophylaxis vs no thromboprophylaxis |
| Oral thromboprophylaxis vs no thromboprophylaxis |
| Initial treatment (within first week) for patients with cancer |
| LMWH vs UFH |
| Fondaparinux vs LMWH |
| DOAC vs LMWH |
| Short-term treatment for patients with active cancer (initial 3-6 mo) |
| LMWH vs VKA |
| DOAC vs VKA |
| DOAC vs LMWH |
| Short-term treatment (3-6 mo) vs observation for patients with cancer and incidental PE |
| Short-term treatment (3-6 mo) vs observation for patients with cancer and SSPE |
| Short-term treatment (3-6 mo) vs observation for patients with cancer and visceral/splanchnic vein thrombosis |
| Keeping CVC vs removing CVC |
| Increasing dose to supratherapeutic levels vs continuing with standard therapeutic dose |
| Adding an IVC filter vs not for patients with cancer and recurrent VTEs, despite therapeutic anticoagulation treatment |
| Long-term treatment (>6 mo) for patients with active cancer and VTE |
| Long-term anticoagulation (>6 mo) vs short-term anticoagulation (3-6 mo) |
| Continuing indefinite anticoagulation vs stopping after completion of a definitive period of anticoagulation |
| DOAC vs LMWH for long-term anticoagulation |